References
- Nickel JC, Moon T. Chronic bacterial prostatitis: an evolving enigma. Urology 2005; 66: 2–8.
- Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus def-inition and classification of prostatitis. JAMA 1999; 282: 236–237.
- Meares EM, Stamey TA. Bacteriologic localization pat-terns in bacterial prostatitis and urethritis. Invest Urol 1968; 5: 492–518.
- Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. J Urol 1999; 162: 369–375.
- Giubilei G, Mondaini N, Crisci A, et al. The Italian ver-sion of the National Institutes of Health Chronic Prostatitis Symptom Index. Eur Urol 2005; 47: 805–811.
- Naber KG, Bishop MC, Bjerklund-Johansen TE, et al. EAU Guidelines on the management of urinary and male gen-ital tract infections. European Association of Urology, 2006. Available at http://www.uroweb.org. Accessed September 19, 2006.
- Naber KG, Sorgel F. Antibiotic therapy—rationale and evidence for optimal drug concentrations in prostatic and sem-inal fluid and in prostatic tissue. Andrologia 2003; 35: 331–335
- Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64: 2221–2234.
- Prats G, Rossi V, Salvatori E, Mirelis B. Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther 2006; 4: 27–41.
- Cervigni M, Orticelli G, Bologna M, et al. Single-dose prulifloxacin versus single-dose pefloxacin in the treatment of acute uncomplicated urinary tract infection in women. Urogynaecol Int J 2003; 17: 69–77.
- Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infec-tions. Urol Int 2005; 74: 326–331.
- Fadda G, Nicoletti G, Schito GC, Tempera G. Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J Chemother 2005; 17: 251–257.
- Shimizu M, Tabata M, Hara T, Araake M, Watabe H, Nishino T. In vitro short-term bactericidal activity and accumu-lation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin. Jpn J Antibiotic 2002; 55: 791–799.
- Prats G, Roig C, Miro E, Navarro F, Mirelis B. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 2002; 21: 328–334. Erratum in: Eur J Clin Microbiol Infect Dis 2004; 23: 422.
- Tullio V, Cuffini AM, Bonino A, Ianni Palarchio A, Rossi V, Carlone NA. Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF 3013 against Klebsiella pneumoniae. Drugs Exp Clin Res 1999; 25: 1–11.
- Weidner W, Ludwig M, Brahler E, Schiefer HG. Outcome of antibiotic therapy with Ciprofloxacin in chronic bacterial prostatitis. Drugs 1999; 58 Suppl 2: 103–106.
- Reato G, Cuffini AM, Tullio V, et al. Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils. Int J Antimicrob Agents 2004; 23: 150–154.
- Bundrick W, Heron SP, Ray P, et al. Levofloxacin ver-sus ciprofloxacin in the treatment of chronic bacterial prostati-tis: a randomized double-blind multicenter study. Urology 2003; 62: 537–541.